The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
Phase 3
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT00171639
- Locations
- 🇺🇸
Southern AZ VA Health Care System, Tucson, Arizona, United States
🇺🇸Washington VA Medical Center, Washington, District of Columbia, United States
🇺🇸VA Medical Center-Long Beach, Long Beach, California, United States
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
Phase 4
Terminated
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 93
- Registration Number
- NCT00171847
- Locations
- 🇩🇪
Novartis Investigative Site, Tuebingen, Germany
ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
Phase 4
Completed
- Conditions
- Renal Transplantation
- Interventions
- Drug: Calcineurin Inhibitors (CNI)Drug: Steroids
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 394
- Registration Number
- NCT00170846
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT00171951
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, United Kingdom
🇺🇸Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU., Portland, Oregon, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT00154349
A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT00154336
- Locations
- 🇬🇧
Novartis Investigative site, Stoke-on-Trent, United Kingdom
🇬🇧Multiple Sites, Multiple Cities, United Kingdom
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
Phase 3
Completed
- Conditions
- Glioblastoma MultiformeAstrocytoma
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 240
- Registration Number
- NCT00154375
- Locations
- 🇩🇪
Novartis Investigative Site, Duelmen, Germany
Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT00154297
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients
Phase 4
Completed
- Conditions
- Kidney Transplantation
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT00154206
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
Phase 4
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT00154232
© Copyright 2025. All Rights Reserved by MedPath